Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...
WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy ...
FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.
AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...
AstraZeneca’s Imfinzi (durvalumab), in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel), has been approved by the US FDA to treat adult ...
The U.S. Food and Drug Administration has approved Imfinzi (durvalumab) in combination with standard-of-care FLOT ...
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for the treatment of adult ...
The US Food and Drug Administration approved AstraZeneca’s Imfinzi (durvalumab) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, ...
The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as neoadjuvant and ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
TipRanks on MSN
Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European ...
AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback